CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
MolecularMD Corp. has entered into a license agreement to obtain rights to commercialize patent-pending intellectual property pertaining to use of LKB1 for diagnostic, prognostic, and predictive uses in humans in non-small cell lung cancer.
Read More »